<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554343</url>
  </required_header>
  <id_info>
    <org_study_id>B412201734396</org_study_id>
    <nct_id>NCT03554343</nct_id>
  </id_info>
  <brief_title>Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium</brief_title>
  <official_title>Sun May Arise on SMA : Newborn Screening of SMA in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional de la Citadelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AveXis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association Belge contre les Maladies neuro Musculaires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional de la Citadelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medico-economic study of Newborn screening of Spinal Muscular Atrophy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this project is to demonstrate the feasibility and the medico-economic impact of a
      spinal muscular atrophy neonatal screening in a European country. We propose a
      3-year-neonatal screening program in Southern Belgium (Wallonia-Brussels Federation) where
      there is 59.000 newborns/year, among whom 6 are affected by spinal muscular atrophy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cases detected</measure>
    <time_frame>march 2018-March 2021</time_frame>
    <description>Number of cases detected, false negative and false positive cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SMA</measure>
    <time_frame>March 2018-March 2021</time_frame>
    <description>to gather epidemiological data on SMA in Wallonia-Brussels Federation (carrier frequency, number of cases/year).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180000</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>All newborn from Southern Belgium</arm_group_label>
    <description>All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>test for SMN1 exon 7 deletion</intervention_name>
    <description>Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers</description>
    <arm_group_label>All newborn from Southern Belgium</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA is exctracted from the Guthrie Dried Blood Test Analysis is performed by the genetic
      department of Liege University Hospital
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All newborns
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All newborns in southern Belgium

        Exclusion Criteria:

          -  Newborns whose parents refuse screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Servais, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRMN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Servais, MD, PhD</last_name>
    <phone>+3243216127</phone>
    <email>laurent.servais@paediatrics.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRMN, Hôpital La Citadelle</name>
      <address>
        <city>Liege</city>
        <state>Wallonia</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Servais, MD, PhD</last_name>
      <phone>+3243216127</phone>
      <email>laurent.servais@paediatrics.ox.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Dangouloff</last_name>
      <phone>+33662438138</phone>
      <email>tdangouloff.screeningsma@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Hubert Caberg, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois Boemer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Régional de la Citadelle</investigator_affiliation>
    <investigator_full_name>Laurent Servais</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>newborn screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

